Treatment of Guillain-Barré Syndrome
Initiate intravenous immunoglobulin (IVIg) at 0.4 g/kg/day for 5 consecutive days (total dose 2 g/kg) in any adult with GBS who cannot walk unaided within 2–4 weeks of symptom onset. 1, 2, 3
First-Line Immunotherapy Selection
IVIg is the preferred first-line treatment because it is easier to administer, more widely available, achieves higher treatment-completion rates, and requires no special equipment or vascular access compared to plasma exchange. 4, 1, 2
Plasma exchange (PE) is an equally effective alternative, delivered as 200–250 mL/kg total plasma volume over 4–5 sessions within 4 weeks of symptom onset, but it necessitates specialized equipment, central venous access, and carries a higher incidence of adverse effects. 4, 1, 3, 5
Both treatments demonstrate equivalent clinical efficacy when initiated within the critical 2-week window after neuropathic symptom onset, as most patients reach maximum disability within this timeframe. 1, 6, 3
Do not combine PE followed immediately by IVIg or vice versa, as sequential treatment provides no additional benefit over either therapy alone. 1, 3, 5
Critical Monitoring and Admission Criteria
Admit all patients to an inpatient unit with rapid ICU transfer capability, as approximately 20% develop respiratory failure requiring mechanical ventilation, which can occur rapidly and sometimes without obvious dyspnea. 1, 2
Assess respiratory function immediately using the "20/30/40 rule": patients are at high risk for respiratory failure if vital capacity <20 mL/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O. 1
Perform serial pulmonary function testing (vital capacity and negative inspiratory force) daily to detect early respiratory compromise. 1
Monitor continuously for dysautonomia, including blood pressure and heart-rate instability, pupillary dysfunction, and bowel/bladder dysfunction, as cardiovascular complications contribute to the 3–10% mortality rate. 1, 2
Medications to Avoid
- Immediately discontinue β-blockers, intravenous magnesium, fluoroquinolones, aminoglycosides, and macrolides, as these agents worsen neuromuscular transmission and can exacerbate weakness. 1, 2
Pain Management
Initiate gabapentinoids (gabapentin or pregabalin) or duloxetine for neuropathic pain as part of comprehensive supportive care; these can be started concurrently with IVIg without drug interaction. 1, 2, 3
Recognize that severe pain affects at least one-third of patients at 1 year and may persist for more than a decade, requiring aggressive early management. 1, 2
Expected Treatment Response and Common Pitfalls
Approximately 40% of patients do not improve in the first 4 weeks following immunotherapy—this does not necessarily indicate treatment failure, as progression might have been worse without therapy. 1, 2, 6
Treatment-related fluctuations (TRFs) occur in 6–10% of patients, defined as disease progression within 2 months after initial treatment-induced improvement or stabilization. 1, 2, 6
Repeating a full course of IVIg or PE is common practice for TRFs, although high-quality evidence supporting this approach is lacking. 1, 6
Consider reclassifying to acute-onset CIDP if progression continues beyond 8 weeks from onset or if the patient experiences ≥3 TRFs, which occurs in approximately 5% of patients initially diagnosed with GBS. 1, 3
Corticosteroid Use: Important Exception
Do not use corticosteroids alone for idiopathic GBS, as they provide no benefit and are not recommended. 1, 3, 5
However, if GBS develops during immune-checkpoint inhibitor therapy, permanently discontinue the checkpoint inhibitor and add concurrent corticosteroids (methylprednisolone 2–4 mg/kg/day) to IVIg or PE. 1
For Grade 3–4 severity in checkpoint-inhibitor-related GBS, consider pulse corticosteroid therapy (methylprednisolone 1 g/day for 5 days) as an adjunct. 1
Supportive Care Essentials
Implement daily neurologic examinations to track disease progression and treatment response. 1
Provide standard preventive measures for deep vein thrombosis, pressure ulcers, hospital-acquired infections (pneumonia, UTIs), and constipation/ileus. 1
Arrange a structured rehabilitation program involving physiotherapists, occupational therapists, and rehabilitation specialists before discharge. 1, 2
Implement exercise programs (range-of-motion, stationary cycling, walking, strength training) to improve physical fitness, walking ability, and independence in activities of daily living, but monitor intensity to avoid fatigue. 1
Prognosis and Long-Term Outcomes
Approximately 80% of patients regain independent walking ability by 6 months, with functional recovery continuing for several years and improvements reported beyond 5 years after onset. 1, 2, 7
Overall mortality ranges from 3–10%, primarily due to cardiovascular and respiratory complications occurring in both acute and recovery phases. 1, 2, 7
Advanced age and severe disease at onset are recognized risk factors for poorer outcomes. 1, 2
Fatigue affects 60–80% of survivors and is a major disabling symptom that can persist long-term. 1
Recurrence is uncommon (2–5% of patients) but higher than the background lifetime risk (0.1%), and prior GBS is not an absolute contraindication to vaccination, though vaccination within one year of a GBS episode should be discussed with specialists. 1, 2
Diagnostic Workup (Do Not Delay Treatment)
Obtain an immediate neurology consultation for every suspected GBS case to ensure timely diagnosis and management. 1
Perform lumbar puncture to assess for albumino-cytological dissociation (elevated protein with normal cell count), but do not exclude GBS if CSF protein is normal during the first week of illness. 1, 3
Conduct nerve-conduction studies and EMG to support the diagnosis and classify the neuropathy pattern; repeat after 2–3 weeks if early studies are normal. 1, 3
Do not wait for antiganglioside antibody test results before starting treatment; initiate immunotherapy based on clinical suspicion. 1
Order MRI of the spine with contrast to exclude compressive lesions and assess for nerve-root enhancement. 1